Patients with antiphospholipid antibodies (APLA) are predisposed to develop thrombosis, however the standardization of anti-cardiolipin (aCL) and anti-beta 2 glycoprotein I (β2-GPI) Ab assays are challenging. Therefore we decided to test the performance of a new chemiluminescent assay (CLIA), and assayed aCL and aβ2-GPI IgG/M in serum from 120 healthy individuals, 108 patients with idiopathic venous thrombosis, 78 patients with antiphospholipid syndrome (APS), and 64 non-thrombotic APLA-carriers using CLIA IDS-iSYS. Very good (aCL/aβ2-GPI IgG) to moderate (aCL/aβ2-GPI IgM) agreement with a commercial and an in house ELISA assay were observed and, in particular, CLIA demonstrated the highest sensitivity in aβ2-GPI IgG detection. Finally, aCL/aβ2-GPI Ab capacity to predict the thrombotic risk was tested showing for CLIA a significant odds ratio (OR) when considering double positivity for aCL/aβ2-GPI IgG, aCL IgG at high levels, and aβ2-GPI IgG at high levels. In conclusion, CLIA improves aβ2-GPI IgG detection and thrombotic risk assessment.

具有抗磷脂抗体（APLA）的患者易患血栓形成，但是抗心磷脂（aCL）和抗β2糖蛋白I（β2-GPI）Ab检测的标准化具有挑战性。因此，我们决定测试一种新的化学发光测定（CLIA）的性能，并测定了120例健康个体，108例特发性静脉血栓形成，78例抗磷脂综合征（APS）和使用CLIA IDS-iSYS的64种非血栓性APLA载体。观察到与商业和内部ELISA测定的非常好（aCL /aβ2-GPIIgG）到中度（aCL /aβ2-GPIIgG）一致性，尤其是CLIA在aβ2-GPIIgG检测中表现出最高的灵敏度。最后，当考虑对aCL /aβ2-GPIIgG，高水平的aCL IgG和高水平的aβ2-GPIIgG的双重阳性时，测试了aCL /aβ2-GPI的Ab预测血栓风险的能力，从而显示CLIA的显着优势比（OR）。 。总之，CLIA可改善aβ2-GPIIgG检测和血栓形成风险评估。